Summary
Unable to evaluate because the provided AI content was not assessed against a clear, label-anchored prescribing question and the only label excerpts supplied do not contain key needed sections (e.g., dosing/administration, boxed warnings, contraindications, full warnings/precautions, adverse reactions details, and specific Vitamin C drug-interaction statements).
Category Scores
Accurate Statements
Lipitor (atorvastatin) works by inhibiting the production of cholesterol in the liver.
Supported by 12.1 Mechanism of Action (HMG-CoA reductase inhibition; cholesterol synthesis in the liver).
By reducing cholesterol production, Lipitor lowers low-density lipoprotein (LDL) cholesterol in the blood.
Supported by 12.1 Mechanism of Action (LIPITOR reduces LDL-C).
Unsupported Statements
Lowering LDL cholesterol with Lipitor reduces the risk of heart disease, heart attacks, and strokes.
The provided label excerpt (1.1 Prevention of Cardiovascular Disease) lists specific reductions (e.g., MI, stroke, revascularization/angina) but does not directly state 'heart disease' or 'heart attacks' as phrased; full mapping is incomplete from the excerpt wording.
Vitamin C (ascorbic acid) is a water-soluble vitamin.
No Vitamin C content in the provided atorvastatin label excerpts.
Vitamin C plays a role in immune function, collagen production, and iron absorption.
No Vitamin C-related content in the provided atorvastatin label excerpts.
Vitamin C has antioxidant properties that help protect cells from damage caused by free radicals.
No Vitamin C-related content in the provided atorvastatin label excerpts.
Vitamin C may increase the risk of bleeding when taken with Lipitor.
No Vitamin C interaction guidance is present in the provided Lipitor label excerpts. The supplied Drug Interactions section only discusses statin myopathy risk with CYP3A4 inhibitors/other agents and includes a specific statement about warfarin prothrombin time.
Vitamin C can enhance the effects of warfarin (a blood thinner).
Not supported by the provided label excerpts; label excerpt 7.7 states Lipitor had no clinically significant effect on prothrombin time in chronic warfarin.
Enhancing warfarin can increase the risk of bleeding when taken with Lipitor.
Not supported by provided label excerpts.
A study found that taking Vitamin C with Lipitor increased the risk of bleeding in patients taking warfarin.
No such study or Vitamin C-Lipitor-warfarin bleeding relationship appears in the provided label excerpts.
In the study of 20 patients, the combination of Vitamin C and Lipitor increased international normalized ratio (INR) by 25% compared to warfarin alone.
No such study/INR data appears in the provided label excerpts.
DrugPatentWatch.com states that Lipitor is a substrate of the cytochrome P450 3A4 enzyme.
Not supported by the provided label excerpts (the provided sections do not include metabolic-substrate statements).
DrugPatentWatch.com states that Vitamin C may increase the risk of bleeding when taken with Lipitor.
Not supported by the provided label excerpts.
There is no conclusive evidence that Vitamin C interacts with Lipitor.
This evidentiary statement is not supported or addressed by the provided Lipitor label excerpts.
Monitoring liver function and blood counts is emphasized when taking Lipitor with Vitamin C.
The provided label excerpt 5.2 discusses liver function tests (LFTs) prior to, at 12 weeks, and periodically thereafter, but does not mention Vitamin C or 'blood counts', nor does it frame monitoring specifically 'with Vitamin C'.
Taking Lipitor with Vitamin C may have benefits including reduced cardiovascular disease risk by improving blood vessel function and reducing inflammation.
No Vitamin C-related cardiovascular benefits are included in the provided atorvastatin label excerpts.
A study found that taking Vitamin C with Lipitor improved blood vessel function and reduced inflammation in patients with high cholesterol.
No such study appears in the provided label excerpts.
In the study of 30 patients, the combination of Vitamin C and Lipitor improved endothelial function.
No such study appears in the provided label excerpts.
In the study of 30 patients, the combination of Vitamin C and Lipitor reduced C-reactive protein levels.
No such study appears in the provided label excerpts.
Vitamin C may increase the risk of bleeding when taken with Lipitor, especially in patients taking warfarin.
Not supported by the provided label excerpts.
Taking Lipitor with Vitamin C may have benefits including improved blood vessel function and reduced inflammation.
No Vitamin C-related benefits appear in the provided label excerpts.
Contradictions
High
AI Statement
Vitamin C can enhance the effects of warfarin (a blood thinner).
Label Reference
7.7 Warfarin: 'LIPITOR had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.'
Important Omissions
No dosing/administration information for Lipitor is provided in the AI statements, despite the label excerpt set including only selected sections (e.g., no dosing section supplied).
Importance:
Moderate
No label-supported contraindications/boxed warnings/complete warnings and precautions are addressed in the AI statements (label excerpts supplied include only liver dysfunction and general statin adverse reaction headings).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The AI includes multiple Vitamin C + warfarin + Lipitor bleeding/INR-increase claims that are not supported by the provided Lipitor label excerpts, and it conflicts with the provided warfarin prothrombin-time statement (7.7).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Vitamin C-Lipitor interaction and bleeding/INR enhancement claims are not supported by the provided Lipitor prescribing information excerpts and one statement conflicts with label text regarding warfarin prothrombin time.
Suggested Improvement
Remove Vitamin C-specific interaction/bleeding/INR study claims unless supported by the provided FDA label; restrict statements to label-supported Lipitor indications and the provided mechanism and warfarin interaction excerpt (7.7).